Return to search

ArchiMed Fund II closes at $376.2 mln

ArchiMed said Sept. 18 that it closed its Med II fund at its hard cap of 315 million euros ($376.2 million). ArchiMed’s second fund attracted commitments from nearly 30 investors, mainly from the United States and Europe. ArchiMed invests in all healthcare sectors, including medtech, biopharma, care services and preventive healthcare. ArchiMed, of Lyon, France, was formed in 2014 by former 3i healthcare executives.

PRESS RELEASE

September 18, 2017 – ArchiMed closed investment in its Med II fund at its hard cap of €315 million, more than 25% above its initial target and more than double the size of its 2015 maiden fund. The significantly oversubscribed Med II fund went through a four-month fundraising campaign.

ArchiMed was formed in 2014 by former 3i Healthcare leaders as one of Europe’s very first lower midmarket private equity firms focused exclusively on healthcare investments. Its inaugural Med I fund raised €150 million from mostly European investors. ArchiMed’s second fund attracted commitments from nearly 30 investors, mainly from the United States and Europe. Within Europe, investors from the Benelux, France, Germany, Switzerland and the UK are well represented among Med II’s limited partners. Investors include endowments, foundations, funds-of-funds, family offices, banks, insurers and sovereign wealth funds. ArchiMed engages in both unleveraged growth investments and leveraged buyouts. It invests in all healthcare sectors, including Medtech, Biopharma, Care Services and Preventive Healthcare. “Our mission is to help smaller healthcare companies profitably expand through accelerated internationalization and innovation,” says Denis Ribon, ArchiMed chairman and previously the global head of healthcare at 3i. “ArchiMed’s fundraising success is testament not only to the appeal of a private equity team with a topdecile track record, it’s also an example of the traction knowledgeable specialists in relatively uncrowded market spaces have when the traditional buyout arena is seen as crowded and expensive,” says Nicolas de Nazelle, managing partner at Triago, which acted as placement agent for both Med II and Med I. The Med I fund, now nearly fully invested, has completed a first, full exit, generating close to a 400 percent internal rate of return, and arranged two refinancings of portfolio companies, all of which has returned more than a third of invested capital.

About ArchiMed – ArchiMed is an independent private equity team dedicated to the healthcare sector in Europe. The ArchiMed team includes partners Denis Ribon, Vincent Guillaumot, Robin Filmer-Wilson, Loïc Kubitza and operating partner Christoph Böhmer. ArchiMed invests in all healthcare sectors, targeting profitable, established European healthcare companies and investing between €5 million and €50 million per transaction. In the last sixteen years the ArchiMed team has invested more than €1 billion in 20-plus companies, achieving a total return of over 2.6 times invested capital. ArchiMed is currently the reference shareholder of Swiss-Italian company Medistream, French firms Polyplus and Fytexia, British firms Deallus and RehabWorks, Italian-French company Micromed and Italian company Primo.